Clinic Roundup

Mimetogen Pharmaceuticals Inc., of Montreal, said Phase II data for MIM-D3 in dry eye disease showed the drug was well tolerated and significantly improved signs and symptoms of dry eye at the low and high doses. Detailed data will be presented at a scientific conference. MIM-D3 is a small-molecule mimetic of nerve growth factor.